CLINICAL_TRIALS
trial_result
· 2012-03-27
Clinical Trial Update: Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer [Phase 3]
Summary
Phase 3 trial update on axitinib as second-line therapy for metastatic renal cell cancer completed with results posted in 2012.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Kidney Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2012-03-27